IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. Stat Biosci 2017 Jun;9(1):1-12
Date
10/03/2017Pubmed ID
28966695Pubmed Central ID
PMC5617361DOI
10.1007/s12561-016-9144-1Scopus ID
2-s2.0-84962297658 (requires institutional sign-in at Scopus site)Abstract
Despite improvements in operative management and therapies, overall survival rates in advanced ovarian cancer have remained largely unchanged over the past three decades. Although it is possible to identify high-risk patients following surgery, the knowledge does not provide information about the genomic aberrations conferring risk, or the implications for treatment. To address these challenges, we developed an integrative pathway-index model and applied it to messenger RNA expression from 458 patients with serous ovarian carcinoma from the Cancer Genome Atlas project. The biomarker derived from this approach, IPI59, contains 59 genes from six pathways. As we demonstrate using independent datasets from six studies, IPI59 is strongly associated with overall and progression-free survival, and also identifies high-risk patients who may benefit from enhanced adjuvant therapy.
Author List
Choi J, Ye S, Eng KH, Korthauer K, Bradley WH, Rader JS, Kendziorski CAuthors
William H. Bradley MD Professor in the Obstetrics and Gynecology department at Medical College of WisconsinJanet Sue Rader MD Chair, Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin
